Effects of Oxiracetam on Learning and Memory in Animals

Mondadori, Cesare; Classen, W.; Borkowski, J.; Ducret, Thomas; Buerki, H.; Schadé, A.

doi:10.1097/00002826-198609003-00006

Cited by 27 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these drugs have multiple modes of action and produce only weak AMPA receptor activation and it is unclear how significant their ampakine actions are in producing their positive effects. Animal studies suggest memory and wakefulness enhancement properties of several racetams (Barad et al, 1998;Grossman et al, 2011;Lelkes et al, 1998;Mondadori et al, 1986;Samartgis et al, 2012;Scheuer et al, 1999;Trofimov et al, 2005;Tushmalova et al, 1995). It is noteworthy that animal experiments focused on restoring age-impaired cognitive functions (Gualtieri et al, 2002).…”

Section: Perspectivesmentioning

confidence: 99%

Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review

Fond¹,

Micoulaud-Franchi²,

Brunel³

et al. 2015

Psychiatry Research

View full text Add to dashboard Cite

Section: Perspectivesmentioning

confidence: 99%

Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review

Fond¹,

Micoulaud-Franchi²,

Brunel³

et al. 2015

Psychiatry Research

View full text Add to dashboard Cite

“…Although animal studies suggest memory and wakefulness enhancement properties of several racetams [170][171][172][173][174][175][176][177], the effectiveness of piracetam or piracetam-like molecules was not explored in healthy adults to date. An explanation could be that all animal data focused on restoring age-impaired cognitive functions [11].…”

Section: Perspectives Racetamsmentioning

confidence: 99%

Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review

Micoulaud¹

2015

J Clinic Res Bioeth

View full text Add to dashboard Cite

The term neuroenhancement refers to improvement in the cognitive, emotional and motivational functions of healthy individuals through inter alia, the use of drugs. This popular topic attracts attention both from the general public and the scientific community. Our objective is to summarize in a synthetic review the data of randomized placebo-controlled trials that assessed cognitive effects of administration of neuroenhancers in non-sleep-deprived healthy adults compared to placebo. The major outcomes were attention, memory, learning, executive functions, and vigilance/wakefulness. Details on the pharmacological profile, effectiveness and safety for each drug are provided. We classify them according to their recognized major primary mode of action, namely catecholaminergics (methylphenidate,

show abstract

“…In elderly patients with mild to moderate dementia, 800 mg of oxiracetam twice daily was effective in enhancing both attentional activities and other, more complex, neuropsychological functions (3). Oxiracetam has been shown to improve learning and memory in normal animals as Please send reprint requests to : Dr Hans-Peter Gschwind, Ciba-Geigy Limited, K-136.2.83, CH-4002 Basle, Switzerland well as in animals with acute and chronic cerebral impainnent (4,5).…”

Section: Introductionmentioning

confidence: 99%

Absorption and disposition of14C-labelled oxiracetam in rat, dog and man

Gschwind

Schütz

Wigger

et al. 1992

European Journal of Drug Metabolism and Pharmacokinetics

View full text Add to dashboard Cite

The absorption and disposition of the nootropic drug oxiracetam (4-hydroxy-2-oxo-pyrrolidine-1-yl acetamide) were studied in rats and dogs (10 mg/kg i.v. and 10, 50 and 3000 mg/kg p.o.) and two healthy male volunteers (800 mg p.o.) using a [14C]-labelled preparation. Peroral absorption of [14C]-oxiracetam was incomplete in rats (28-42%), high in dogs (81-90%) and intermediate in man (about 56%). The rate of absorption was high in all species. Elimination was biphasic and the concentration of total radioactivity in blood and plasma declined rapidly with an initial elimination half-life of 1-3 h in all species. The specific systemic exposure to [14C]-oxiracetam was lowest in the rat, intermediate in the dog and highest in man. In all species the systemically available radioactivity was nearly exclusively excreted in urine in the form of unmetabolized oxiracetam. Whole-body autoradiography and quantitative determination of the radioactivity in various organs following i.v. and p.o. administration of [14C]-oxiracetam to rats demonstrated extensive distribution of the compound with high levels in kidney, liver, lung and skin, and very low levels in the brain. The radioactivity was rapidly eliminated from the body and minimal accumulation was observed upon repeated administration of 10 mg/kg for 8 days. Levels in the brain were still low, but higher than following a single dose, indicating slow diffusion across the blood-brain barrier. In pregnant rats treated with [14C]-oxiracetam radioactivity passed reversibly and to a limited extent through the placenta into fetal tissue.

show abstract

Effects of Oxiracetam on Learning and Memory in Animals

Cited by 27 publications

References 0 publications

Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review

Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review

Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review

Absorption and disposition of14C-labelled oxiracetam in rat, dog and man

Contact Info

Product

Resources

About